サマリー

インドネシア、マレーシア、タイ、フィリピン、ベトナムのIgA腎症市場は、2023年の15,716.44千米ドルから2034年には42,340.41千米ドルに達すると予測され、2024年から2034年の予測期間においてCAGR 10.1％で成長すると予測される。
市場区分
インドネシア、マレーシア、タイ、フィリピン、ベトナムのIgA腎症市場：疾患タイプ（原発性IgA腎症、続発性IgA腎症）、タイプ（診断と治療）、人口タイプ（成人、老人、小児）、投与経路（経口、非経口、その他）別エンドユーザー（病院、専門クリニック、診断センター、外来ケアセンター、在宅医療、その他）、流通チャネル（小売販売、直接入札、その他）、国（インドネシア、マレーシア、タイ、フィリピン、ベトナム）-産業動向と2034年までの予測
インドネシア、マレーシア、タイ、フィリピン、ベトナムのIgA腎症市場ダイナミクスの概要

促進要因
- IgA腎症患者数の増加
阻害要因
- IgA腎症の治療費の高さ

機会

- 医薬品開発のための市場プレイヤー間の協力
市場プレイヤー

インドネシア、マレーシア、タイ、フィリピン、ベトナムのIgA腎症市場で事業を展開する主な市場参入企業は以下の通り：

- サン・ファーマシューティカル・インダストリーズ社
- ファイザー
- ザイダス・グループ
- ノバルティスAG
- アークレイUSA社
- テバ・ファーマシューティカルUSA Inc.

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF INDONESIA, MALAYSIA, THAILAND, PHILIPPINES & VIETNAM IGA NEPHROPATHY MARKET 17
1.4 LIMITATIONS 19
1.5 MARKETS COVERED 20
2 MARKET SEGMENTATION 22
2.1 MARKETS COVERED 22
2.2 YEARS CONSIDERED FOR THE STUDY 23
2.3 CURRENCY AND PRICING 23
2.4 DBMR TRIPOD DATA VALIDATION MODEL 24
2.5 MULTIVARIATE MODELLING 27
2.6 DBMR MARKET POSITION GRID 29
2.7 VENDOR SHARE ANALYSIS 30
2.8 SECONDARY SOURCES 31
2.9 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHT 34
4.1 PESTEL ANALYSIS 35
4.2 PORTER’S FIVE FORCES 36
4.3 PREVALENCE OF IGA NEPHROPATHY 37
4.4 INCIDENCE OF IGA NEPHROPATHY 37
4.5 CURRENT TREATMENT OF IGA NEPHROPATHY 37
4.6 EXPENDITURE OF IGA NEPHROPATHY 37
4.7 DETECTION METHODS OF IGA NEPHROPATHY 38
5 MARKET OVERVIEW 40
5.1 DRIVERS 42
5.1.1 RISE IN THE NUMBER OF CASES OF IGA NEPHROPATHY 42
5.1.2 INCREASE IN THE AVAILABILITY OF IGA-TARGETED PIPELINE DRUGS 42
5.1.3 INCREASING INVESTMENT IN R&D OF DRUG DISCOVERY 42
5.1.4 INCREASING PRODUCT APPROVALS FOR IGA NEPHROPATHY TREATMENT 43
5.2 RESTRAINTS 43
5.2.1 HIGH COST OF IGA NEPHROPATHY TREATMENT 43
5.2.2 DELAYED DIAGNOSIS OF IGA NEPHROPATHY 44
5.2.3 POOR PLANNING OF IGA NEPHROPATHY TREATMENT IN LOW-INCOME COUNTRIES 44
5.2.4 INABILITY TO EFFECTIVELY TREAT IGA NEPHROPATHY 44
5.3 OPPORTUNITIES 45
5.3.1 COLLABORATION AMONG MARKET PLAYERS FOR DRUG DEVELOPMENT 45
5.3.2 INCREASE IN GOVERNMENT FUNDING FOR RESEARCH PURPOSES 45
5.3.3 INCREASING TREND OF NOVEL DIAGNOSIS PROCEDURE 46
5.4 CHALLENGES 46
5.4.1 LOW AWARENESS AMONG THE POPULATION REGARDING KIDNEY DISEASE 46
5.4.2 STRINGENT GOVERNMENT REGULATIONS RELATED TO THE APPROVAL OF NEUROENDOCRINE TUMOR DRUG 47
6 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY DISEASE TYPE 48
6.1 OVERVIEW 49
6.2 PRIMARY IGA NEPHROPATHY 52
6.3 SECONDARY IGA NEPHROPATHY 52
7 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY TYPE 53
7.1 OVERVIEW 54
7.2 DIAGNOSIS 57
7.2.1 URINE TEST 57
7.2.1.1 URINE ALBUMIN-TO-CREATININE RATIO 57
7.2.1.2 DIPSTICK TEST FOR ALBUMIN AND BLOOD 58
7.2.2 BLOOD TEST 58
7.2.3 IOTHALAMATE CLEARANCE TEST 58
7.2.4 KIDNEY BIOPSY 58
7.2.5 OTHERS 58
7.3 TREATMENT 58
7.3.1 BLOOD PRESSURE LOWERING AGENTS 59
7.3.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 59
7.3.1.1.1 LISINOPRIL 59
7.3.1.1.2 ENALAPRIL 60
7.3.1.1.3 RAMIPRIL 60
7.3.1.1.4 BENAZEPRIL 60
7.3.1.1.5 OTHERS 60
7.3.1.2 ANGIOTENSIN RECEPTOR BLOCKERs 60
7.3.1.2.1 LOSARTAN 60
7.3.1.2.2 VALSARTAN 61
7.3.1.2.3 IRBESARTAN 61
7.3.1.2.4 OTHERS 61
7.3.2 IMMUNOSUPPRESANT 61
7.3.2.1 CYCLOPHOSPHAMIDE 61
7.3.2.2 AZATHIOPRINE 61
7.3.2.3 CORTICOSTEROIDS 61
7.3.2.3.1 METHYLPREDNISONE 62
7.3.2.3.2 PREDNISOLONE 62
7.3.2.3.3 OTHERS 62
7.3.2.4 OTHERS 62
7.3.3 DIURETICS 63
7.3.3.1 FUROSEMIDE 63
7.3.3.2 TORSEMIDE 63
7.3.3.3 BUMETANIDE 63
7.3.3.4 OTHERS 63
7.3.4 BLOOD CHOLESTEROL LOWERING AGENTS 63
7.3.4.1 ATROVASTATIN 64
7.3.4.2 SIMVASTATIN 64
7.3.4.3 ROSUVASTATIN 64
7.3.4.4 FLUVASTATIN 64
7.3.4.5 PRAVASTATIN 64
7.3.4.6 OTHERS 64
7.3.5 SUPPLEMENTS 65
7.3.5.1 OMEGA-3-FATTY ACIDS 65
7.3.5.2 VITAMIN E 65
7.3.5.3 OTHERS 65
7.3.6 OTHERS 65
8 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY POPULATION TYPE 66
8.1 OVERVIEW 67
8.2 ADULTS 70
8.3 GERIATRIC 70
8.4 PEDIATRIC 70
9 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION 71
9.1 OVERVIEW 72
9.2 ORAL 75
9.2.1 TABLETS/PILLS 75
9.2.2 CAPSULES 75
9.2.3 OTHERS 75
9.3 PARENTERAL 76
9.3.1 INTRAVENOUS 76
9.3.2 SUBCUTANEOUS 76
9.3.3 OTHERS 76
9.4 OTHERS 76
10 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY END USER 77
10.1 OVERVIEW 78
10.2 HOSPITALS 81
10.2.1 PRIVATE 81
10.2.2 PUBLIC 81
10.3 SPECIALTY CLINICS 81
10.4 DIAGNOSTIC CENTERS 81
10.5 AMBULATORY CARE CENTERS 81
10.6 HOME HEALTHCARE 82
10.7 OTHERS 82
11 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL 83
11.1 OVERVIEW 84
11.2 RETAIL SALES 87
11.2.1 HOSPITAL PHARMACY 87
11.2.2 ONLINE PHARMACY 87
11.2.3 RETAIL PHARMACY 87
11.3 DIRECT TENDER 87
11.4 OTHERS 87
12 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM 88
12.1 MALAYSIA 89
12.2 THAILAND 95
12.3 INDONESIA 101
12.4 PHILIPPINES 107
12.5 VIETNAM 113
13 INDONESIA, MALAYSIA, PHILIPPINES, VIETNAM, AND THAILAND IGA NEPHROPATHY MARKET, COMPANY LANDSCAPE 119
13.1 COMPANY SHARE ANALYSIS: INDONESIA, MALAYSIA, PHILIPPINES, VIETNAM, AND THAILAND 119
14 SWOT ANALYSIS 120
15 COMPANY PROFILE 121
15.1 SUN PHARMACEUTICAL INDUSTRIES LTD 121
15.1.1 COMPANY SNAPSHOT 121
15.1.2 REVENUE ANALYSIS 122
15.1.3 PRODUCT PORTFOLIO 122
15.1.4 RECENT DEVELOPMENTS 123
15.3 PFIZER INC. 124
15.3.1 COMPANY SNAPSHOT 124
15.3.2 REVENUE ANALYSIS 124
15.3.3 PRODUCT PORTFOLIO 125
15.3.4 RECENT DEVELOPMENT 125
15.4 ZYDUS GROUP. 126
15.4.1 COMPANY SNAPSHOT 126
15.4.2 REVENUE ANALYSIS 126
15.4.3 PRODUCT PORTFOLIO 127
15.4.4 RECENT DEVELOPMENTS 127
15.5 NOVARTIS AG 128
15.5.1 COMPANY SNAPSHOT 128
15.5.2 REVENUE ANALYSIS 128
15.5.3 PRODUCT PORTFOLIO 129
15.5.4 RECENT DEVELOPMENTS 129
15.6 ARKRAY USA, INC. 131
15.6.1 COMPANY SNAPSHOT 131
15.6.2 PRODUCT PORTFOLIO 131
15.6.3 RECENT DEVELOPMENTS 131
15.7 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 132
15.7.1 COMPANY SNAPSHOT 132
15.7.2 REVENUE FINANCIALS 132
15.7.3 PRODUCT PORTFOLIO 133
15.7.4 RECENT DEVELOPMENTS 133
16 QUESTIONNAIRE 135
17 RELATED REPORTS 138